analyt
method
quantit
measur
product
possibl
antiimmun
escap
activ
felin
infecti
periton
viru
fipv
felin
plasma
develop
valid
sampl
prepar
consist
solidphas
extract
step
mcx
cartridg
use
intern
standard
analysi
separ
acquiti
uplc
tm
beh
c
reversedphas
column
mm
mm
id
use
isocrat
elut
acetonitril
formic
acid
water
mobil
phase
compound
subsequ
quantifi
mrm
mode
micromass
quattro
premier
tm
xe
tripl
quadrupol
mass
spectromet
use
thermo
scientif
exact
tm
orbitrap
mass
spectromet
made
possibl
confirm
propos
fragment
pattern
valid
studi
accord
ec
requir
carri
method
show
good
perform
linear
behaviour
observ
ng
ml
rang
relev
real
sampl
analysi
accuraci
precis
within
criteria
request
ec
requir
throughout
concentr
rang
extract
recoveri
matrix
effect
higher
method
success
use
monitor
felin
plasma
intraven
subcutan
oral
administr
formul
determin
pharmacokinet
paramet
limit
quantif
ng
ml
limit
detect
ng
ml
propos
method
also
show
good
characterist
analysi
plasma
anim
speci
human
plasma
infect
cat
felin
coronaviru
fcov
two
differ
outcom
cat
infect
avirul
fcovstrain
usual
develop
mild
enter
virul
fcovstrain
caus
progress
usual
fatal
vascul
known
felin
infecti
periton
fip
fip
one
common
infecti
caus
death
young
cat
neither
effect
treatment
vaccin
avail
enigmat
diseas
pathogenesi
fulli
understood
recent
work
research
group
gave
new
insight
interact
infect
monocyt
vivo
target
cell
viru
immun
system
demonstr
viru
develop
multipl
mechan
evad
host
humor
immun
system
viru
replic
monocyt
ensur
protect
omnipres
antibodi
inhibit
viral
protein
express
plasma
membran
achiev
intracellular
retent
viral
protein
antibodyinduc
intern
protein
reach
plasma
membran
mechan
offer
protect
recognit
antibodi
thu
antibodydepend
complementmedi
lysi
adcml
cellmedi
cytotox
adcc
adcml
occur
either
format
membran
attack
complex
effector
cell
carri
complement
receptor
neutrophil
monocyt
macrophag
adcc
execut
neutrophil
monocyt
macrophag
natur
killer
cell
immuneevas
mechan
could
explain
fipv
infect
cell
elimin
despit
high
antibodi
titr
found
infect
cat
intern
pathway
fulli
character
found
depend
among
other
myosin
light
chain
kinas
mlck
full
hydrochlorid
potent
select
mlck
inhibitor
found
good
candid
vivo
block
immuneevas
intern
might
thu
form
basi
new
innov
antiimmun
evas
therapi
immuneevas
mechan
fipv
block
cat
enabl
overcom
infect
antiimmun
evas
therapi
complet
new
approach
control
chronic
viral
diseas
offer
follow
potenti
advantag
compar
exist
antivir
therapi
continu
administr
chemic
requir
associ
problem
relat
resist
lead
elimin
viru
appli
differ
virus
use
immunoevas
process
chemic
develop
mie
univers
japan
studi
function
mlck
activ
famili
naphthalen
deriv
select
mlck
inhibitor
structur
shown
fig
well
relat
mlck
inhibitor
till
patent
file
compound
current
commerci
avail
larg
chemic
compani
sigmaaldrich
calbiochem
alexxi
vwr
although
never
use
vivo
antivir
compound
administ
rat
mice
preserv
lung
intestin
epitheli
barrier
stressor
lipopolysaccharideinduc
injuri
mlck
possibl
target
drug
intend
reliev
lung
bowel
injuri
sepsi
control
paracellular
permeabl
design
effect
dosag
regimen
compound
treatment
fip
viral
infect
cat
determin
major
pharmacokinet
paramet
c
max
peak
plasma
concentr
max
time
reach
peak
concentr
halflif
elimin
auc
area
plasma
concentr
versu
time
curv
must
achiev
paramet
evalu
plasma
concentr
versu
time
profil
drug
administr
suffici
number
anim
purpos
reliabl
sensit
analysi
method
drug
plasma
must
avail
develop
subsequ
valid
method
determin
felin
plasma
present
discuss
paper
knowledg
determin
relat
compon
anim
plasma
publish
yet
also
determin
bodi
fluid
andor
tissu
human
anim
origin
describ
yet
demonstr
novelti
approach
cleanup
plasma
sampl
two
major
strategi
follow
evalu
first
one
base
liquidliquid
extract
ethyl
acet
second
one
involv
solidphas
extract
spe
step
oasi
mcx
mixedmod
cation
exchang
sorbent
cartridg
extract
inject
onto
uplc
ultra
perform
liquid
chromatographi
instrument
compon
measur
esimsm
electrospray
ioniz
tandem
mass
spectrometri
sinc
extract
ethyl
acet
shown
prone
variabl
matrix
effect
method
cleanup
mcx
cartridg
retain
valid
experi
show
therebi
good
perform
characterist
sensit
enough
limit
quantif
loq
ng
ml
limit
detect
lod
ng
ml
could
establish
final
shown
practic
use
monitor
plasma
concentr
time
profil
administr
intraven
subcutan
oral
drug
formul
cat
use
pharmacokinet
analysi
method
also
show
potenti
quantit
analysi
plasma
anim
speci
human
plasma
purchas
sigma
bornem
belgium
stock
solut
concentr
mg
ml
prepar
methanol
store
c
stabl
least
month
dilut
stock
solut
methanol
result
work
solut
g
ml
g
ml
work
solut
store
c
stabl
least
month
solvent
use
mobil
phase
water
acetonitril
uplc
grade
biosolv
valkenswaard
netherland
addit
mobil
phase
formic
acid
lcm
grade
biosolv
methanol
water
use
sampl
cleanup
hplc
grade
vwr
leuven
belgium
reagent
use
sampl
prepar
ammonia
solut
hydrochlor
acid
fume
pro
analysi
grade
purchas
merck
darmstadt
germani
trichloroacet
acid
tca
ethyl
acet
sodium
hydroxid
pellet
naoh
dichloromethan
use
preliminari
experi
sampl
cleanup
evalu
pro
analysi
grade
purchas
merck
l
plasma
sampl
transfer
cap
ml
microcentrifug
cup
spike
l
work
solut
g
ml
intern
standard
blank
sampl
l
use
prepar
calibr
curv
also
spike
l
differ
work
solut
vortex
mix
l
hcl
solut
ad
vortex
mix
sampl
centrifug
rpm
min
cleanup
supernat
perform
solidphas
extract
oasi
mcx
cartridg
mg
ml
water
milford
usa
cartridg
condit
subsequ
ml
methanol
ml
water
ml
hcl
solut
load
sampl
passag
last
sampl
drop
cartridg
rins
ml
water
ml
hcl
solut
dri
vacuum
elut
ml
ammonia
solut
methanol
vv
eluat
evapor
dryness
c
gentl
stream
nitrogen
ga
dri
residu
redissolv
l
methanolwat
vv
mixtur
vortex
transfer
nylon
filter
millipor
billerica
usa
autosampl
vial
l
aliquot
inject
onto
uplc
column
lc
system
consist
acquiti
uplc
tm
binari
solvent
manag
sampl
manag
water
chromatograph
separ
achiev
use
acquiti
uplc
tm
beh
c
reversedphas
column
mm
mm
id
water
column
maintain
temperatur
c
mobil
phase
acetonitril
mobil
phase
b
solut
formic
acid
water
mobil
phase
deliv
uplc
column
flow
rate
ml
min
total
run
time
min
use
follow
gradient
program
min
b
min
linear
b
min
b
min
linear
b
min
b
remark
elut
isocrat
part
uplc
run
ie
first
min
gradient
part
function
suffici
rins
column
two
sampl
inject
uplc
column
effluent
interfac
micromass
quattro
premier
tm
xe
mass
spectromet
instrument
water
equip
esi
ion
sourc
use
posit
ion
mode
divert
valv
use
send
uplc
effluent
directli
wast
first
min
last
min
chromatograph
run
rest
lc
run
elut
column
uplc
effluent
sent
detector
instrument
calibr
solut
mg
ml
nai
accord
manufactur
instruct
thereaft
instrument
tune
direct
infus
solut
g
ml
esi
sourc
l
min
combin
lc
mobil
phase
use
tunion
follow
tune
paramet
found
give
optim
detect
capillari
voltag
kv
cone
voltag
v
extractor
voltag
v
rf
len
v
sourc
temperatur
c
desolv
temperatur
c
desolv
ga
l
h
cone
ga
l
h
optim
collis
energi
msm
mode
correspond
nearli
fragment
proton
molecul
collisioninduc
dissoci
cid
found
ev
follow
mrm
transit
use
promin
product
ion
retain
quantif
respect
use
masslynx
softwar
water
studi
fragment
pattern
thermo
scientif
waltham
usa
exact
tm
orbitrap
mass
spectromet
use
solut
g
ml
therefor
infus
hesi
sourc
l
min
use
follow
tune
paramet
spray
voltag
kv
capillari
voltag
v
tube
len
voltag
v
skimmer
voltag
v
capillari
temperatur
c
sheath
ga
arbitrari
unit
auxiliari
ga
arbitrari
unit
spare
ga
arbitrari
unit
fragment
obtain
combin
insourc
cid
collis
energi
ev
fragment
hcd
higher
energi
collision
dissoci
collis
cell
collis
energi
ev
instrument
infus
experi
calibr
posit
neg
ioniz
mode
accord
manufactur
instruct
ensur
mass
accuraci
result
three
blank
plasma
sampl
differ
origin
use
valid
experi
blank
inhous
blank
depart
pharmacolog
toxicolog
biochemistri
faculti
veterinari
medicin
ghent
univers
look
dirti
confirm
consist
pellet
ultracentrifug
step
follow
addit
l
hcl
see
section
use
major
part
valid
work
blank
leftov
plasma
depart
medicin
clinic
biolog
small
anim
faculti
veterinari
medicin
ghent
univers
contain
citratephosphatedextros
solut
adenin
look
clear
confirm
fact
littl
pellet
observ
mention
ultracentrifug
step
use
determin
blank
blank
depart
medicin
clinic
biolog
small
anim
faculti
veterinari
medicin
ghent
univers
look
dirti
highli
lipid
confirm
consist
pellet
ultracentrifug
step
well
lipid
layer
supernat
also
use
determin
paramet
evalu
valid
experi
accord
guidelin
ec
possibl
linear
accuraci
precis
within
betweenday
limit
quantif
limit
detect
carri
specif
stabil
extract
extract
recoveri
matrix
effect
linear
evalu
calibr
curv
lower
rang
level
ng
ml
calibr
curv
higher
rang
level
ng
ml
differ
analysi
day
curv
fit
linear
curv
equat
ax
b
weigh
instrument
respons
x
analyt
concentr
good
linear
correl
coeffici
r
must
goodnessoffit
coeffici
g
must
level
ng
ml
level
ng
ml
accuraci
precis
rsd
evalu
withinday
level
ng
ml
n
limit
accuraci
level
ng
ml
level
ng
ml
ng
ml
level
ng
ml
toler
precis
given
horwitz
equat
rsd
max
ng
ml
level
respect
evalu
betweenday
accuraci
precis
perform
level
ng
ml
level
lower
rang
also
supplementari
level
ng
ml
higher
rang
n
differ
analysi
day
use
toler
accuraci
precis
ng
ml
level
respect
limit
quantif
loq
lowest
level
criteria
accuraci
precis
fulfil
limit
detect
lod
determin
base
averag
sn
valu
found
loq
sampl
n
use
sn
criterion
specif
evalu
control
presenc
absenc
peak
retent
time
blank
plasma
sampl
extract
carri
evalu
inject
solvent
highest
calibr
control
presenc
absenc
peak
retent
time
stabil
extract
express
ratio
averag
area
respect
measur
ng
ml
plasma
sampl
n
store
c
h
autosampl
extract
compar
one
ng
ml
plasma
sampl
n
analyz
directli
extract
extract
recoveri
express
ratio
averag
area
respect
measur
ng
ml
plasma
sampl
n
compar
one
blank
plasma
sampl
extract
spike
extract
amount
n
matrix
effect
express
ratio
averag
area
blank
sampl
spike
extract
equival
amount
ng
ml
sampl
n
area
refer
solut
contain
amount
compon
liquid
chromatographi
mass
spectrometri
relat
compound
use
intern
standard
could
easili
separ
acquiti
uplc
tm
beh
c
reversedphas
column
mm
mm
id
use
formic
acid
acetonitril
mobil
phase
probabl
commonli
use
solvent
system
lcm
analysi
differ
chemic
structur
compon
iatom
clatom
naphthalen
part
see
fig
give
howev
differ
polar
molecular
mass
da
make
isocrat
separ
realli
challeng
earlier
elut
compon
retent
time
min
chromatograph
condit
describ
section
elut
min
later
min
see
fig
chromatogram
standard
solut
fig
show
besid
chemic
structur
also
mass
spectra
obtain
direct
infus
standard
solut
g
ml
esi
sourc
combin
lc
mobil
phase
use
tunion
best
fig
msm
mass
chromatogram
standard
solut
equival
ng
ml
sampl
blank
plasma
spike
equival
ng
ml
sampl
extract
blank
plasma
spike
ng
ml
blank
plasma
sampl
spike
ng
ml
loq
blank
plasma
sampl
incur
plasma
sampl
concentr
measur
ng
ml
cat
treat
intraven
mgkg
bw
h
administr
chromatogram
spike
sampl
shown
concern
blank
concentr
plasma
sampl
ng
ml
chromatogram
upper
trace
repres
lower
trace
signal
obtain
posit
ion
mode
probabl
compon
incorpor
eg
natom
easili
proton
ms
major
ion
mz
observ
respect
correspond
proton
molecul
mh
compon
molecular
mass
respect
base
clearli
also
ion
lower
intens
mz
observ
due
clisotop
cid
product
ion
spectra
compon
show
predomin
ion
mz
therefor
use
mrm
transit
quantif
accord
mass
frontier
softwar
highchem
ltd
bratislava
slovakia
correspond
moieti
compon
proton
charg
site
rearrang
rhc
softwar
modul
fragment
mechan
expert
system
provid
inform
basic
fragment
rearrang
process
base
literatur
start
usersuppli
chemic
structur
major
product
ion
higher
mz
also
observ
mz
respect
accord
mass
frontier
correspond
iodonaphthalen
chloronaphthalen
moieti
compon
proton
induct
cleavag
also
sever
common
fragment
lower
mz
present
product
ion
spectra
mz
correspond
accord
mass
frontier
smaller
fragment
moieti
compon
result
complex
fragment
mechan
predomin
fragment
ion
could
confirm
reason
certainti
infus
g
ml
solut
hesi
sourc
exact
orbitrap
mass
spectromet
instrument
allow
high
mass
accuraci
measur
fragment
ion
relat
theoret
mass
fragment
gener
mass
frontier
softwar
mass
error
mm
mass
differ
measur
mass
theoret
mass
theoret
mass
ppm
obtain
fragment
ion
mz
respect
low
mass
error
confirm
fragment
mechan
propos
mass
frontier
softwar
see
aim
develop
extract
procedur
simpl
rapid
possibl
sinc
pharmacokinet
studi
number
sampl
substanti
still
robust
enough
allow
reliabl
quantif
sever
extract
cleanup
method
evalu
briefli
discuss
point
concern
independ
preced
extract
cleanup
procedur
seem
filter
devic
use
end
extract
procedur
allow
extract
inject
onto
uplc
system
shown
well
result
shown
retain
sever
filter
membran
type
see
tabl
best
result
obtain
nylon
filter
devic
mm
millipor
remark
unknown
reason
recoveri
even
significantli
confirm
independ
second
assay
simplest
extract
procedur
tri
consist
deprotein
step
tca
briefli
l
plasma
sampl
l
wv
tca
solut
ad
vortex
mix
sampl
centrifug
rpm
min
supernat
transfer
nylon
filter
devic
l
aliquot
inject
onto
lc
column
mean
signal
spike
plasma
sampl
n
compar
refer
solut
amount
treat
way
either
due
low
recoveri
import
matrix
effect
investig
perform
elucid
second
extract
procedur
test
deprotein
step
acetonitril
follow
liquidliquid
extract
dichloromethan
adapt
briefli
l
plasma
sampl
l
acetonitril
ad
vortex
mix
sampl
centrifug
rpm
min
ml
dichloromethan
ad
supernat
vortex
mix
sampl
centrifug
rpm
min
upper
aqueou
layer
transfer
nylon
filter
devic
l
aliquot
inject
onto
lc
column
procedur
show
use
sinc
peak
measur
probabl
due
fact
remain
aqueou
phase
third
extract
procedur
evalu
liquidliquid
extract
ethyl
acet
briefli
l
plasma
samplecondit
either
l
hcl
solut
l
naoh
solut
ml
ethyl
acet
ad
sampl
roll
min
roll
bank
centrifug
rpm
min
upper
organ
phase
transfer
glass
tube
evapor
dryness
c
gentl
stream
nitrogen
residu
reconstitut
l
methanolwat
vv
mixtur
transfer
nylon
filter
devic
l
aliquot
inject
onto
lc
column
expect
best
result
obtain
plasma
sampl
condit
l
naoh
solut
ngroup
deproton
favour
transfer
organ
phase
mean
signal
spike
plasma
sampl
n
compar
refer
solut
amount
acidifi
plasma
noncondit
plasma
assay
use
blank
plasma
differ
origin
differ
result
observ
mean
signal
spike
plasma
sampl
n
much
lower
compar
howev
shown
signific
matrix
effect
sinc
extract
blank
plasma
sampl
spike
show
decreas
signal
n
compar
refer
solut
level
actual
recoveri
therefor
still
yet
instead
appar
blank
plasma
yet
anoth
origin
recoveri
low
signific
matrix
effect
even
case
observ
compromis
establish
loq
low
ng
ml
evid
extract
method
variabl
matrix
effect
observ
allow
reliabl
quantif
improv
observ
ethyl
acet
replac
dichloromethan
extract
solvent
appar
recoveri
obtain
respect
noncondit
alkalin
acidifi
plasma
fact
appar
recoveri
acid
condit
higher
alkalin
condit
might
indic
matrix
effect
even
pronounc
use
dichloromethan
extract
solvent
compar
ethyl
acet
fourth
extract
procedur
involv
use
solidphas
extract
cleanup
step
procedur
use
oasi
hlb
mg
ml
extract
cartridg
test
plasma
sampl
first
treat
l
vv
ammonia
solut
thereaft
load
onto
cartridg
condit
success
ml
meoh
ml
h
ml
vv
ammonia
solut
cartridg
wash
ml
h
dri
vacuum
compon
elut
ml
acetonitril
eluat
evapor
dryness
c
gentl
stream
nitrogen
residu
reconstitut
l
methanolwat
vv
mixtur
transfer
nylon
filter
devic
l
aliquot
inject
onto
lc
column
recoveri
poor
standard
mixtur
spike
plasma
sampl
time
n
indic
well
retain
hlb
cartridg
much
promis
result
obtain
use
mcx
instead
hlb
cartridg
describ
section
differ
step
extract
procedur
evalu
obtain
extract
combin
high
recoveri
suffici
cleanup
allow
analysi
uplcmsm
minim
possibl
matrix
effect
analyt
respons
observ
liquidliquid
extract
procedur
tabl
behaviour
standard
solut
g
ml
vv
solut
passag
differ
filter
membran
type
assay
mean
result
n
manufactur
machereynagel
first
assay
b
second
independ
assay
evalu
influenc
wash
step
ammonia
concentr
elut
solvent
recoveri
mcx
cartridg
evalu
ng
ml
solut
water
result
n
replac
l
hcl
solut
l
tca
wv
solut
ad
plasma
ultracentrifug
step
preced
load
sampl
onto
mcx
cartridg
result
cleaner
extract
sinc
tca
solut
power
remov
plasma
protein
howev
recoveri
margin
compon
despit
fact
cleaner
solut
appli
onto
cartridg
result
evalu
experi
rins
procedur
mcx
cartridg
load
sampl
allow
wash
residu
matrix
compon
summar
tabl
seen
best
recoveri
obtain
wash
step
success
water
hcl
solut
surprisingli
unknown
reason
wash
procedur
opposit
order
result
import
loss
compon
supplementari
third
wash
step
organ
solvent
methanol
ad
supplementari
select
wash
addit
aqueou
phase
also
result
import
loss
analyt
therefor
includ
final
procedur
ammonia
ad
elut
solvent
methanol
disrupt
bind
deproton
ngroup
facilit
recoveri
compon
sinc
recoveri
decreas
increas
ammonia
concentr
elut
solvent
see
tabl
lowest
concentr
ammonia
retain
final
extract
method
equival
mcx
cartridg
isolut
biotag
uppsala
sweden
scx
column
mg
ml
also
evalu
altern
extract
cartridg
although
recoveri
seem
quit
compar
problem
occur
inject
extract
onto
uplc
column
name
excess
peak
broaden
shift
retent
time
extract
procedur
base
solidphas
cleanup
mcx
cartridg
describ
section
subject
valid
experi
evalu
perform
characterist
method
result
summar
tabl
seen
signal
measur
mrm
mode
ms
instrument
linear
wide
rang
ng
ml
r
g
requir
good
linear
rang
true
higher
rang
level
rang
ng
ml
accuraci
analysi
method
evalu
differ
level
ng
ml
n
good
compar
allow
toler
see
tabl
withinday
precis
rsd
analysi
method
evalu
level
even
excel
take
account
rsd
max
valu
given
horwitz
equat
see
tabl
behaviour
also
observ
sampl
spike
ng
ml
n
use
blank
differ
origin
differ
behaviour
extract
blank
see
section
indic
robust
method
see
tabl
also
betweenday
result
accuraci
precis
evalu
ng
ml
level
lower
rang
also
ng
ml
level
higher
rang
differ
analysi
day
satisfactori
see
tabl
loq
establish
ng
ml
lowest
level
criteria
accuraci
precis
could
fulfil
lod
calcul
ng
ml
determin
averag
sn
six
ng
ml
sampl
use
accuraci
precis
evalu
use
sn
criterion
specif
analysi
method
guarante
sinc
interf
peak
observ
retent
time
blank
see
fig
carryov
concern
sinc
peak
measur
solvent
methanolwat
vv
mixtur
inject
immedi
ng
ml
spike
plasma
sampl
stabil
extract
store
c
h
verifi
decreas
signal
compon
observ
time
period
recoveri
analysi
method
accept
compon
respect
import
howev
method
free
signific
matrix
effect
well
shown
compar
area
blank
sampl
spike
extract
area
standard
solut
contain
amount
see
fig
chromatogram
typic
obtain
sampl
blank
test
despit
differ
composit
behaviour
extract
see
section
biggest
decreas
signal
observ
combin
blank
method
shown
practic
use
determin
plasma
sampl
cat
treat
formul
either
intraven
subcutan
inject
oral
administr
determin
concentr
versu
time
profil
necessari
pharmacokinet
evalu
typic
profil
obtain
one
cat
intraven
administr
shown
fig
seen
compound
show
typic
profil
twocompartment
pharmacokinet
model
indic
good
distribut
bodi
applic
method
evalu
toward
determin
plasma
anim
speci
human
plasma
therefor
extract
recoveri
matrix
tabl
result
valid
experi
analysi
method
sampl
extract
cleanup
mcx
cartridg
perform
blank
unless
specifi
otherwis
blank
blank
effect
evalu
canin
rabbit
chicken
porcin
bovin
human
plasma
result
summar
tabl
seen
method
give
extract
recoveri
rang
respect
canin
rabbit
chicken
porcin
human
plasma
lowest
valu
correspond
canin
plasma
highest
recoveri
obtain
human
plasma
recoveri
compar
one
found
felin
plasma
see
tabl
bovin
plasma
extract
recoveri
significantli
lower
close
due
fact
pellet
ultracentrifug
step
plasma
sampl
addit
l
n
hcl
solut
substanti
gelatin
aspect
result
import
loss
analyt
step
compar
plasma
speci
howev
lower
extract
recoveri
tabl
evalu
extract
recoveri
matrix
effect
analysi
method
plasma
speci
canin
rabbit
chicken
porcin
bovin
plasma
human
plasma
determin
n
level
ng
ml
extract
recoveri
matrix
effect
remain
reproduc
rsd
n
minor
modif
presp
step
might
consid
bovin
plasma
increas
lower
extract
recoveri
matrix
effect
accept
plasma
differ
anim
speci
test
well
human
plasma
leastposit
result
increas
signal
case
chicken
plasma
decreas
signal
case
rabbit
plasma
overal
ratio
signal
actual
use
quantif
sampl
involv
experi
summar
tabl
give
rsd
indic
quantif
rel
independ
origin
plasma
indic
method
gener
applic
design
limit
felin
plasma
interest
sinc
least
also
dog
system
corona
viru
infect
report
uplcmsm
method
develop
quantit
felin
plasma
solidphas
extract
mcx
cartridg
found
necessari
sampl
cleanup
step
avoid
matrix
effect
detect
ms
instrument
howev
method
remain
rather
simpl
time
consum
allow
analysi
suffici
number
sampl
reason
time
period
valid
method
show
good
perform
characterist
possibl
also
plasma
anim
speci
human
plasma
also
practic
use
method
shown
determin
plasma
concentr
versu
time
profil
administr
cat
determin
pharmacokinet
need
design
adequ
dosag
regimen
